electroCore (NASDAQ:ECOR – Get Free Report) is one of 510 public companies in the “Healthcare Equipment & Supplies” industry, but how does it compare to its rivals? We will compare electroCore to similar companies based on the strength of its analyst recommendations, dividends, valuation, risk, institutional ownership, profitability and earnings.
Analyst Ratings
This is a breakdown of current recommendations and price targets for electroCore and its rivals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| electroCore | 1 | 1 | 1 | 0 | 2.00 |
| electroCore Competitors | 4323 | 10550 | 18353 | 839 | 2.46 |
electroCore presently has a consensus price target of $18.00, suggesting a potential upside of 266.97%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 27.44%. Given electroCore’s higher possible upside, research analysts clearly believe electroCore is more favorable than its rivals.
Institutional and Insider Ownership
26.7% of electroCore shares are held by institutional investors. Comparatively, 40.3% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 7.8% of electroCore shares are held by insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares electroCore and its rivals gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| electroCore | $32.03 million | -$13.97 million | -3.53 |
| electroCore Competitors | $1.90 billion | $138.28 million | 5.83 |
electroCore’s rivals have higher revenue and earnings than electroCore. electroCore is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Volatility & Risk
electroCore has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500. Comparatively, electroCore’s rivals have a beta of 2.58, indicating that their average stock price is 158% more volatile than the S&P 500.
Profitability
This table compares electroCore and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| electroCore | -33.46% | N/A | -74.21% |
| electroCore Competitors | -191.42% | -197.84% | -21.82% |
Summary
electroCore rivals beat electroCore on 10 of the 13 factors compared.
About electroCore
electroCore is a medical technology company that develops non-invasive bioelectronic therapies. Its products use non-invasive vagus nerve stimulation (nVNS), which delivers gentle electrical stimulation through the skin to activate the vagus nerve. The company’s gammaCore device is used for the treatment of certain headache conditions, including migraine and cluster headache, subject to its regulatory clearances and indications. electroCore also offers Truvaga, a consumer wellness product that uses non-invasive vagus nerve stimulation.
Receive News & Ratings for electroCore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for electroCore and related companies with MarketBeat.com's FREE daily email newsletter.
